Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units

Completed

Conditions studied: Covid19

In brief

This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th, 2020.

Key facts

Study ID

NCT04829552

Run by

Corewell Health East

People needed

704

Starts

2020-03-10

Expected to finish

2020-04-15

Last updated by the study team

2021-04-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >18 years old
• positive reverse transcription-polymerase chain reaction (rRT-PCR) test for the qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens.
• Intensive care unit (ICU) patient or Step-down unit (SDU) patient on invasive mechanical ventilation, BiPAP, 100% non-rebreather mask, or high flow oxygen or supplemental oxygen of at least 4 liters per minute nasal cannula.
• peak d-dimer levels exceeding 1,000 mcg/mL at any time during admission.

You may not qualify if…

• Hospital length of stay less than 5 days.
• Hemorrhage before ICU/SDU admission.
• Treatment with an anticoagulant other than low molecular weight heparin or unfractionated heparin.
• Constant treatment with the same dose of anticoagulant for less than 5 days.

Where it is running

• Beaumont Health System (BHS) — Royal Oak, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.